Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lebrikizumab in adults with perennial allergic rhinitis
CTR20241692Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lebrikizumab in perennial rhinitis, sponsored by Eli Lilly and Company. Started Mar 2025; status: active.
02
Drugs
lebrikizumab
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on CTR20241692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241692.